NOVELTY - Strontium salts of a mono-alkylesters of fumaric acid are new. USE - In the manufacture of a pharmaceutical composition for combating tissue degenerative processes; and for the treatment of psoriasis, psoriatic arthritis, neurodermatitis, inflammatory bowel disease (such as Crohn's disease), ulcerative colitis, autoimmune diseases (such as polyarthritis, multiple sclerosis (MS), Juvenile-onset diabetes, Hashimoto's thyroiditis, Grave's disease, SLE (systemic lupus erythematosus), Sjogren's syndrome, Pernicious anemia, Chronic active (lupoid) hepatitis, rheumatoid arthritis (RA) and optic neuritis), pain (such as radicular pain, pain associated with radiculopathy, neuropathic pain or sciatica/sciatic pain). For the treatment and/or prevention of rejection following organ transplantation, sarcoidosis, necrobiosis lipoidica and/or granuloma annulare (all claimed). ADVANTAGE - The compounds provides an alternative and potential improved treatment with a reduction in gastro-intestinal related side effects (including diarrhea, stomach ache, stomach pain, abdominal pain, abdominal cramps, nausea, flatulence, tenesmus, meteorism, an increased frequency of stools, a feeling of fullness and upper abdominal cramps) upon oral administration; and provides pharmaceutical composition for controlled release. DETAILED DESCRIPTION - Strontium salts (I) of a mono-(1-5C)alkylesters of fumaric acid are new. An INDEPENDENT CLAIM is also included for preparation of (I).
|Country||International Bureau of the World Intellectual Property Organization (WIPO)|
|Publication status||Published - 2006|
Country: United States